Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients.

Trial Profile

Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 09 Feb 2010 Actual initiation date (Aug 2005) and actual patient number (57) added as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top